Biotechnology News and Research

RSS

Shrink announces agreement to produce high content screening tool for biotech R&D subsidiary

Shrink Nanotechnologies, Inc. an innovative nanotechnology company developing products and licensing opportunities in the alternative energy industry, medical diagnostics and sensors and biotechnology research and development tools businesses, announced today that it has entered into an agreement to produce a high content screening tool for its biotech R&D subsidiary, Shrink Chips LLC.

25 Oct 2010

Scientists use Affymetrix custom microarray to advance malarial study

Affymetrix, Inc. announced today that an international team of researchers led by scientists at Boston College, the Broad Institute, and Imperial College London used an Affymetrix custom microarray to advance the study of malaria by assessing the variation in genetic structure and detecting known and novel genetic differences among malaria vector mosquito populations.

25 Oct 2010

New research shows flu virus with D222G mutation can cause pneumonia

A variant of last year's pandemic influenza linked to fatal cases carried a mutation that enabled it to infect a different subset of cells lining the airway, according to new research. The study, due to be published next week in the Journal of Virology, suggests that the mutant virus could have impaired the lungs' ability to clear out germs.

25 Oct 2010

FDA approves REMS for NUVIGIL and PROVIGIL tablets

Cephalon, Inc. today announced that Risk Evaluation and Mitigation Strategies (REMS) for its medications NUVIGIL (armodafinil) Tablets [C-IV] and PROVIGIL (modafinil) Tablets [C-IV] have been approved by the U.S. Food and Drug Administration (FDA).

25 Oct 2010

Research project on food allergy to showcase results at symposium in Nice

A research project on food allergy that involved 25 countries worldwide will showcase some of its results at a symposium in Nice starting today. "What we found won't make it easy to pinpoint which foods carry the biggest risk, as the risk for individual foods varies from country to country," says project coordinator Professor Clare Mills from the Institute of Food Research.

22 Oct 2010

BIOCOM selects partneringONE platform for Global Life Science Partnering Conference

EBD Group, the leading partnering firm for the global life science industry, today announced that BIOCOM has selected partneringONE as the partnering platform for its inaugural Global Life Science Partnering Conference to be held February 22–24, 2011 at the Estancia Hotel and Spa in La Jolla, California. This conference is an exclusive global partnering and networking forum for senior executives and business development professionals of the life science industry.

22 Oct 2010

Astellas suspends patient enrollment from ACT 5 study of KYNAPID

Cardiome Pharma Corp. today announced that its co-development partner, Astellas Pharma US., Inc., has suspended patient enrollment in the ACT 5 study of KYNAPIDTM (vernakalant hydrochloride) Injection following a single unexpected serious adverse event of cardiogenic shock experienced by a patient with atrial fibrillation who received KYNAPID.

22 Oct 2010

Talecris announces publication of PROLASTIN-C study results for AAT deficiency in BML journal

Talecris Biotherapeutics today announced the publication of results from a study showing that PROLASTIN-C (Alpha1-Proteinase Inhibitor [Human]) (A1PI) is as effective as PROLASTIN (Alpha1-Proteinase Inhibitor [Human]) in raising levels of alpha-1 protein in patients with alpha1-antitrypsin (AAT) deficiency.

22 Oct 2010

Cephalon signs convertible note subscription agreement with ChemGenex Pharmaceuticals

Today, Cephalon, Inc. announced the signing of a convertible note subscription agreement with ChemGenex Pharmaceuticals Limited, an Australian-based oncology focused biopharmaceutical company.

22 Oct 2010

Antigene therapy uses light energy to silence gene activity: Review article

Antigene therapy is a promising new treatment strategy that uses a DNA-based drug to pinpoint light energy to a target gene shutting down its activity.

22 Oct 2010

Myrexis to present Phase 2 monotherapy study results of Azixa in patients with GBM

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it will present at the 2010 Society for Neuro-Oncology Scientific Meeting and Education Day, to be held November 18-21, 2010 in Montreal, Canada.

22 Oct 2010

Biogen, Genentech announce new structure of anti-CD20 collaboration

Biogen Idec and Genentech, Inc. a wholly owned member of the Roche Group today announced that they have agreed to amend their collaboration on antibodies targeting CD20.

22 Oct 2010

Advaxis completes patient recruitment in ADXS11-001 phase II study for cervical dysplasia

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, completes recruitment of the first group of patients in its US cervical dysplasia (CIN) phase II study of ADXS11-001 as required for the planned DMSB (safety board) meeting scheduled to be held January 11, 2011.

22 Oct 2010

Celtic Pharma receives US patent for methods to treat breast, colon cancer

Celtic Pharmaceutical Holdings L.P. today announced that the U.S. Patent Office has issued U.S. patent 7,816,323, for novel methods to treat breast and colon cancers using a combination therapy of Xerecept with Avastin.

22 Oct 2010

$1 million Pfizer Fellowship awarded for melanoma research at AusBiotech 2010

Dr Mark Shackleton was last night awarded the 2011 Pfizer Australia Senior Research Fellowship grant for his research proposal at the AusBiotech 2010 Conference Dinner. Professor John Funder, chair of the selection committee, announced this year’s winner, who will use the $1 million, five-year Fellowship for research into ‘Identifying determinants of human melanoma progression’.

21 Oct 2010

Astellas suspends enrollment in ACT 5 study of KYNAPID in atrial fibrillation patients

21 Oct 2010

PolyMedix plans PMX-60056 Phase 2 clinical trial in interventional cardiology

PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has announced plans for a Phase 2 clinical trial of PMX-60056 in interventional cardiology, and the establishment of a focused Heptagonist Clinical Advisory Board (CAB). PMX-60056 is a synthetic small-molecule designed to reverse the anticoagulant activity of heparin and low molecular weight heparins (LMWH).

21 Oct 2010